drugset / Trial / NCT00177307
Safety and Efficacy Study Using Bevacizumab, Capecitabine and Oxaliplatin for Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase II study of the drug combination of Oxaliplatin, Avastin and capecitabine. This is an open-label study.
Timeline
- Start
- 2005-01
- Primary completion
- 2012-02
- Completion
- 2012-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 5 mg/kg | Intravenous |
| Subject | Capecitabine | Small molecule | 1250 mg/m2 | Oral |
| Subject | Oxaliplatin | Small molecule | 85 mg/m2 | Intravenous |